Search Results - "Cremoux, Patricia De"

Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome by Charfi, Lamia, Jouffroy, Thomas, Cremoux, Patricia de, Le Peltier, Nelly, Thioux, Martine, Fréneaux, Paul, Point, Daniel, Girod, Angélique, Rodriguez, José, Sastre-Garau, Xavier

“…Abstract To determine whether human papillomaviruses (HPV) positive tonsillar squamous cell carcinoma (SCC) represent a specific entity, we studied the…”
Get full text

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype by Groheux, David, Majdoub, Mohamed, Sanna, Alice, de Cremoux, Patricia, Hindié, Elif, Giacchetti, Sylvie, Martineau, Antoine, de Roquancourt, Anne, Merlet, Pascal, Visvikis, Dimitris, Resche-Rigon, Matthieu, Hatt, Mathieu, Espié, Marc

“…To investigate parameters based on fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging that are best correlated with pathologic…”
Get full text

Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial by Pierga, Jean-Yves, Bidard, François-Clément, Mathiot, Claire, Brain, Etienne, Delaloge, Suzette, Giachetti, Sylvie, de Cremoux, Patricia, Salmon, Rémy, Vincent-Salomon, Anne, Marty, Michel

“…Purpose: Circulating tumor cells in blood from metastatic breast cancer patients have been reported as a surrogate marker for tumor response and shorter…”
Get full text

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review by Luporsi, Elisabeth, André, Fabrice, Spyratos, Frédérique, Martin, Pierre-Marie, Jacquemier, Jocelyne, Penault-Llorca, Frédérique, Tubiana-Mathieu, Nicole, Sigal-Zafrani, Brigitte, Arnould, Laurent, Gompel, Anne, Egele, Caroline, Poulet, Bruno, Clough, Krishna B., Crouet, Hubert, Fourquet, Alain, Lefranc, Jean-Pierre, Mathelin, Carole, Rouyer, Nicolas, Serin, Daniel, Spielmann, Marc, Haugh, Margaret, Chenard, Marie-Pierre, Brain, Etienne, de Cremoux, Patricia, Bellocq, Jean-Pierre

“…Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as…”
Get full text

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients by Amelot, Aymeric, De Cremoux, Patricia, Quillien, Véronique, Polivka, Marc, Adle-Biassette, Homa, Lehmann-Che, Jacqueline, Françoise, Laurence, Carpentier, Antoine F, George, Bernard, Mandonnet, Emmanuel, Froelich, Sébastien

“…A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a…”
Get full text

Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy by Rodrigues-Ferreira, Sylvie, Nehlig, Anne, Moindjie, Hadia, Monchecourt, Clarisse, Seiler, Cynthia, Marangoni, Elisabetta, Chateau-Joubert, Sophie, Dujaric, Marie-Eglantine, Servant, Nicolas, Asselain, Bernard, deCremoux, Patricia, Lacroix-Triki, Magali, Arnedos, Monica, Pierga, Jean-Yves, André, Fabrice, Nahmias, Clara

“…Predictive biomarkers for tumor response to neoadjuvant chemotherapy are needed in breast cancer. This study investigates the predictive value of 280 genes…”
Get full text

Molecular profiling of patient-derived breast cancer xenografts by Reyal, Fabien, Guyader, Charlotte, Decraene, Charles, Lucchesi, Carlo, Auger, Nathalie, Assayag, Franck, De Plater, Ludmilla, Gentien, David, Poupon, Marie-France, Cottu, Paul, De Cremoux, Patricia, Gestraud, Pierre, Vincent-Salomon, Anne, Fontaine, Jean-Jacques, Roman-Roman, Sergio, Delattre, Olivier, Decaudin, Didier, Marangoni, Elisabetta

“…Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics of their respective…”
Get full text

A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays by MARANGONI, Elisabetta, VINCENT -SALOMON, Anne, REBUCCI, Magali, TRAN -PERENNOU, Carine, SASTRE-GARAU, Xavier, SIGAL-ZAFRANI, Brigitte, DELATTRE, Olivier, DIBRAS, Véronique, POUPON, Marie-France, AUGER, Nathalie, DEGEORGES, Armelle, ASSAYAG, Franck, DE CREMOUX, Patricia, DE PLATER, Ludmilla, GUYADER, Charlotte, DE PINIEUX, Gonzague, JUDDE, Jean-Gabriel

“…Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays. Experimental…”
Get full text

Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line by ABAL, Miguel, BRAS-GONCALVES, Rui, JUDDE, Jean-Gabriel, FSIHI, Hafida, DE CREMOUX, Patricia, LOUVARD, Daniel, MAGDELENAT, Henri, ROBINE, Sylvie, POUPON, Marie-France

“…Mutations in the tumor-suppressor gene p53 have been associated with advanced colorectal cancer (CRC). Irinotecan (CPT-11), a DNA topoisomerase 1 inhibitor,…”
Get full text

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review by Lamy, Pierre-Jean, Allory, Yves, Gauchez, Anne-Sophie, Asselain, Bernard, Beuzeboc, Philippe, de Cremoux, Patricia, Fontugne, Jacqueline, Georges, Agnès, Hennequin, Christophe, Lehmann-Che, Jacqueline, Massard, Christophe, Millet, Ingrid, Murez, Thibaut, Schlageter, Marie-Hélène, Rouvière, Olivier, Kassab-Chahmi, Diana, Rozet, François, Descotes, Jean-Luc, Rébillard, Xavier

“…Abstract Context Prostate cancer stratification is based on tumour size, pretreatment PSA level, and Gleason score, but it remains imperfect. Current research…”
Get full text

Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors by Groheux, David, Hatt, Mathieu, Hindié, Elif, Giacchetti, Sylvie, de Cremoux, Patricia, Lehmann‐Che, Jacqueline, Martineau, Antoine, Marty, Michel, Cuvier, Caroline, Cheze‐Le Rest, Catherine, de Roquancourt, Anne, Visvikis, Dimitris, Espié, Marc

“…BACKGROUND The objective of this prospective study was to evaluate the ability of 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography/computed…”
Get full text

Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma by Peter, Martine, Stransky, Nicolas, Couturier, Jérôme, Hupé, Philippe, Barillot, Emmanuel, de Cremoux, Patricia, Cottu, Paul, Radvanyi, Francois, Sastre-Garau, Xavier

“…To investigate whether integration of HPV DNA in cervical carcinoma is responsible for structural alterations of the host genome at the insertion site, a…”
Get full text

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2 -negative Breast Cancer Patients by DE Cremoux, Patricia, Hamy, Anne-Sophie, Lehmann-Che, Jacqueline, Scott, Véronique, Sigal, Brigitte, Mathieu, Marie-Christine, Bertheau, Philippe, Guinebretière, Jean Marc, Pierga, Jean Yves, Giacchetti, Sylvie, Brain, Etienne, Marty, Michel, Asselain, Bernard, Spyratos, Frédérique, Bièche, Ivan

“…The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor…”
Get full text

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity by Vincent-Salomon, Anne, Gruel, Nadège, Lucchesi, Carlo, MacGrogan, Gaëtan, Dendale, Remi, Sigal-Zafrani, Brigitte, Longy, Michel, Raynal, Virginie, Pierron, Gaëlle, de Mascarel, Isabelle, Taris, Corinne, Stoppa-Lyonnet, Dominique, Pierga, Jean-Yves, Salmon, Rémy, Sastre-Garau, Xavier, Fourquet, Alain, Delattre, Olivier, de Cremoux, Patricia, Aurias, Alain

“…Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like carcinoma spectrum, a feature in agreement with the high…”
Get full text

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts by de Cremoux, Patricia, Dalvai, Mathieu, N’Doye, Olivia, Moutahir, Fatima, Rolland, Gaëlle, Chouchane-Mlik, Olfa, Assayag, Franck, Lehmann-Che, Jacqueline, Kraus-Berthie, Laurence, Nicolas, André, Lockhart, Brian Paul, Marangoni, Elisabetta, de Thé, Hugues, Depil, Stéphane, Bystricky, Kerstin, Decaudin, Didier

“…Several publications have suggested that histone deacetylase inhibitors (HDACis) could reverse the repression of estrogen receptor alpha (ERα) in…”
Get full text

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis by Groheux, David, Martineau, Antoine, Teixeira, Luis, Espié, Marc, de Cremoux, Patricia, Bertheau, Philippe, Merlet, Pascal, Lemarignier, Charles

“…Background This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed…”
Get full text

Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients by PIERGA, Jean-Yves, BONNETON, Charlyne, VINCENT-SALOMON, Anne, DE CREMOUX, Patricia, NOS, Claude, BLIN, Nathalie, POUILLART, Pierre, THIERY, Jean-Paul, MAGDELENAT, Henri

“…Purpose: The presence of tumor cells in bone marrow has been reported to represent an important prognostic indicator in breast cancer, but the clinical…”
Get full text

Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients by Etienne‐Grimaldi, Marie‐Christine, Formento, Patricia, Degeorges, Armelle, Pierga, Jean‐Yves, Delva, Rémi, Pivot, Xavier, Dalenc, Florence, Espié, Marc, Veyret, Corinne, Formento, Jean‐Louis, Francoual, Mireille, Piutti, Magali, de Crémoux, Patricia, Milano, Gérard

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Functional polymorphisms on the VEGF‐A gene, known to be linked to cancer risk or to VEGF‐A plasma concentrations,…”
Get full text

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms by Beau-Faller, Michèle, Blons, Hélène, Domerg, Caroline, Gajda, Dorota, Richard, Nicolas, Escande, Fabienne, Solassol, Jérôme, Denis, Marc G, Cayre, Anne, Nanni-Metellus, Isabelle, Olschwang, Sylviane, Lizard, Sarab, Piard, Fabienne, Pretet, Jean-Luc, de Fraipont, Florence, Bièche, Ivan, de Cremoux, Patricia, Rouquette, Isabelle, Bringuier, Pierre-Paul, Mosser, Jean, Legrain, Michèle, Voegeli, Anne-Claire, Saulnier, Patrick, Morin, Franck, Pignon, Jean-Pierre, Zalcman, Gérard, Cadranel, Jacques

“…Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have limited use as first-line treatment for mutated EGFR metastatic non-small cell lung…”
Get full text

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer by Groheux, David, Sanna, Alice, Majdoub, Mohamed, de Cremoux, Patricia, Giacchetti, Sylvie, Teixeira, Luis, Espié, Marc, Merlet, Pascal, de Roquancourt, Anne, Visvikis, Dimitris, Hatt, Mathieu, Resche-Rigon, Matthieu, Hindié, Elif

“…This study investigated whether (18)F-FDG PET/CT performed at baseline and during neoadjuvant chemotherapy (NAC) was able to early depict estrogen…”
Get full text